LGL Group (NYSEAMERICAN:LGL) Announces Earnings Results

LGL Group (NYSEAMERICAN:LGL) announced its quarterly earnings results on Friday. The industrial products company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.07), FiscalAI reports. LGL Group had a net margin of 1.66% and a return on equity of 0.16%. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.80 million.

LGL Group Stock Down 1.6%

Shares of LGL traded down $0.12 during mid-day trading on Friday, reaching $7.43. 6,750 shares of the stock traded hands, compared to its average volume of 13,059. The firm has a market cap of $48.59 million, a price-to-earnings ratio of 743.74 and a beta of 0.32. The stock has a fifty day simple moving average of $6.95 and a 200 day simple moving average of $7.06. LGL Group has a 12-month low of $5.45 and a 12-month high of $7.57.

Analyst Upgrades and Downgrades

Separately, Zacks Research raised shares of LGL Group to a “hold” rating in a research report on Thursday, May 7th. One research analyst has rated the stock with a Hold rating, According to MarketBeat, the company currently has an average rating of “Hold”.

Institutional Investors Weigh In On LGL Group

An institutional investor recently bought a new position in LGL Group stock. Citadel Advisors LLC purchased a new position in shares of LGL Group, Inc. (The) (NYSEAMERICAN:LGL) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,515 shares of the industrial products company’s stock, valued at approximately $90,000. Citadel Advisors LLC owned 0.25% of LGL Group at the end of the most recent reporting period. 30.28% of the stock is owned by institutional investors and hedge funds.

About LGL Group

LGL Group Inc is a United States–based company specializing in the development and commercialization of digital pathology and molecular imaging systems for research and clinical laboratories. The company’s core focus lies in enabling high-resolution visualization and quantitative analysis of tissue samples, helping scientists and pathologists accelerate biomarker discovery and diagnostic workflows. LGL Group’s platform combines advanced optics, automated slide scanning and image analysis software to deliver end-to-end solutions tailored to oncology, immunology and neuroscience research.

The company’s flagship offerings include whole-slide scanners capable of rapid, high-throughput scanning at resolutions suited for detailed morphometric and fluorescence studies.